CTLA4 and melanoma: While the advent of immunotherapy has brought new hope to patients with advanced melanoma, not all individuals respond to immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 or CTLA-4, with primary or acquired resistance being a persistent obstacle in a subset of patients (36).